NO883974L - Fremgangsmaate for fremstilling av terapeutiske aktive tetrahydro-hydroksypyranon-derivater. - Google Patents

Fremgangsmaate for fremstilling av terapeutiske aktive tetrahydro-hydroksypyranon-derivater.

Info

Publication number
NO883974L
NO883974L NO88883974A NO883974A NO883974L NO 883974 L NO883974 L NO 883974L NO 88883974 A NO88883974 A NO 88883974A NO 883974 A NO883974 A NO 883974A NO 883974 L NO883974 L NO 883974L
Authority
NO
Norway
Prior art keywords
hydroxypyranon
derivatives
procedure
preparation
therapeutic active
Prior art date
Application number
NO88883974A
Other languages
English (en)
Norwegian (no)
Other versions
NO883974D0 (no
Inventor
Alexander Wilhelm Chucholowski
Bruce David Roth
Mark Wallace Creswell
Drago Robert Sliskovic
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO883974D0 publication Critical patent/NO883974D0/no
Publication of NO883974L publication Critical patent/NO883974L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO88883974A 1987-09-08 1988-09-07 Fremgangsmaate for fremstilling av terapeutiske aktive tetrahydro-hydroksypyranon-derivater. NO883974L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9419887A 1987-09-08 1987-09-08
US07/226,190 US4906624A (en) 1987-09-08 1988-08-02 6-(((Substituted)pyridin-3-yl)alkyl)-and alkenyl)-tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis

Publications (2)

Publication Number Publication Date
NO883974D0 NO883974D0 (no) 1988-09-07
NO883974L true NO883974L (no) 1989-03-09

Family

ID=26788605

Family Applications (1)

Application Number Title Priority Date Filing Date
NO88883974A NO883974L (no) 1987-09-08 1988-09-07 Fremgangsmaate for fremstilling av terapeutiske aktive tetrahydro-hydroksypyranon-derivater.

Country Status (10)

Country Link
US (1) US4906624A (da)
EP (1) EP0306929A3 (da)
JP (1) JPH01121266A (da)
KR (1) KR890005089A (da)
AU (1) AU620559B2 (da)
DK (1) DK497488A (da)
FI (1) FI884080A7 (da)
NO (1) NO883974L (da)
NZ (1) NZ226063A (da)
PT (1) PT88442B (da)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169857A (en) * 1988-01-20 1992-12-08 Bayer Aktiengesellschaft 7-(polysubstituted pyridyl)-hept-6-endates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis
DE3854854D1 (de) * 1987-07-10 1996-02-15 Hoechst Ag 3-Desmethyl-mevalonsäurederivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate auf Basis dieser Verbindungen, ihre Verwendung sowie Zwischenprodukte
DE3741509A1 (de) * 1987-12-08 1989-06-22 Hoechst Ag Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte
NO177005C (no) * 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
DE3826814A1 (de) * 1988-08-06 1990-02-08 Hoechst Ag Neue 6-fluor-3,5-dihydroxycarbonsaeuren und deren derivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate und zwischenprodukte
NZ230121A (en) * 1988-08-29 1993-08-26 Squibb & Sons Inc Pyridine and quinoline terminal groups for hmg-coenzyme a reductase inhibitors and pharmaceutical compositions for lowering blood serum cholesterol levels
US5506219A (en) * 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors
US5026698A (en) * 1988-11-02 1991-06-25 Nissan Chemical Industries, Ltd. Thienopyridine type mevalonolactones
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
DE3925636A1 (de) * 1989-08-03 1991-02-07 Bayer Ag Imino-substituierte pyridine
US5183897A (en) * 1989-08-03 1993-02-02 Bayer Aktiengesellschaft Certain intermediate imino-substituted pyridines
DE3929507A1 (de) * 1989-09-06 1991-03-07 Bayer Ag Substituierte amino-pyridine
ZA911046B (en) * 1990-02-26 1992-10-28 Squibb & Sons Inc Quinoline and pyridine anchors for hmg-coa reductase inhibitors
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
US5288928A (en) * 1990-12-21 1994-02-22 Ciba-Geigy Corporation Asymmetrical hydrogenation
EG21314A (en) 1992-07-16 2000-10-31 Driutt Rodney Malcolm Tamper evident closure
AU660132B2 (en) * 1992-12-21 1995-06-08 Bayer Aktiengesellschaft Substituted 4-phenyl-pyridones and 4-phenyl-2-alkoxypyridine
DE4244029A1 (de) * 1992-12-24 1994-06-30 Bayer Ag Neue substituierte Pyridine
DE4309553A1 (de) * 1993-03-24 1994-09-29 Bayer Ag Verfahren zur Herstellung von 3R,5S-(+)-Natrium-erythro-(E)-7-(4-(4-flurophenyl)-2,6-diisopropyl-5-methoxymethyl-pyrid-3-yl)-3,5-dihydroxy-hept-6-enoat
DE19610932A1 (de) * 1996-03-20 1997-09-25 Bayer Ag 2-Aryl-substituierte Pyridine
AR008789A1 (es) * 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
WO2000030616A1 (en) * 1998-11-20 2000-06-02 Rtp Pharma Inc. Dispersible phospholipid stabilized microparticles
US6455554B1 (en) 1999-06-07 2002-09-24 Targacept, Inc. Oxopyridinyl pharmaceutical compositions and methods for use
WO2001021259A2 (en) * 1999-09-21 2001-03-29 Emory University Use and compositions for treating platelet-related disorders using anagrelide
EP1267914B2 (en) * 2000-02-04 2013-11-06 Children's Hospital Research Foundation Use of lysosomal acid lipase for treating atherosclerosis and related diseases
US6627636B2 (en) 2000-06-15 2003-09-30 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US6812345B2 (en) 2000-06-15 2004-11-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US6620821B2 (en) 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
WO2002024193A1 (en) * 2000-09-20 2002-03-28 Skyepharma Canada Inc. Stabilised fibrate microparticles
US8586094B2 (en) * 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
DE10135013A1 (de) * 2001-07-18 2003-01-30 Bayer Ag Herstellung von Pyridylverbindungen
US6835838B2 (en) * 2002-01-28 2004-12-28 Novartis Ag Process for the manufacture of organic compounds
DK1532269T3 (da) 2002-05-09 2012-03-12 Brigham & Womens Hospital 1L1RL-1 som markør for kardiovaskulær sygdom
CA2510319A1 (en) * 2002-12-20 2004-07-15 Thomas J. Smith High pressure compaction for pharmaceutical formulations
EP1510208A1 (en) * 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
AU2005294165B2 (en) 2004-10-06 2012-02-02 The Brigham And Women's Hospital, Inc. Relevance of achieved levels of markers of systemic inflammation following treatment
CA2596426A1 (en) * 2005-01-31 2006-08-10 Mylan Laboratories, Inc. Pharmaceutical composition comprising hydroxylated nebivolol
CA2610694A1 (en) 2005-05-31 2006-12-07 Mylan Laboratories, Inc. Compositions comrising nebivolol
US8119358B2 (en) * 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
US7659281B2 (en) * 2006-04-25 2010-02-09 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors
EP2030025A2 (en) * 2006-06-07 2009-03-04 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
CN101511348B (zh) 2006-08-30 2012-04-18 国立大学法人九州大学 含有包封他汀类之纳米颗粒的药物组合物
EP2541254B1 (en) 2007-04-18 2014-11-12 Health Diagnostic Laboratory, Inc. Diabetes-related biomarkers and methods of use thereof
KR20120139723A (ko) 2010-02-01 2012-12-27 더 호스피탈 포 식 칠드런 재발협착증의 치료 및 예방을 위한 원격 허혈 처치
CN102939054A (zh) 2010-03-31 2013-02-20 儿童医院 远端缺血处理改进心肌梗死之后的结果的用途
CA2800520A1 (en) 2010-04-08 2011-10-13 The Hospital For Sick Children Use of remote ischemic conditioning for traumatic injury
CA2881563C (en) 2012-08-01 2021-07-20 Zahra TAVAKOLI Free flowing, frozen compositions comprising a therapeutic agent
TWI686213B (zh) 2013-03-21 2020-03-01 美商優普順藥物公司美國分部 可注射持續釋放組合物及使用其治療關節之發炎及與發炎有關之疼痛之方法
JP2018531951A (ja) 2015-10-27 2018-11-01 ユープラシア ファーマシューティカルズ インク． 局所麻酔薬の徐放性製剤
WO2024258976A1 (en) * 2023-06-12 2024-12-19 The General Hospital Corporation Statin derivatives and methods of using the same
EP4553080A1 (en) 2023-11-07 2025-05-14 Ustav Organicke Chemie a Biochemie AV CR, v.v.i. Nucleoside derivatives as antiviral agents against coronaviruses

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4375475A (en) * 1979-08-17 1983-03-01 Merck & Co., Inc. Substituted pyranone inhibitors of cholesterol synthesis
IL67322A0 (en) * 1981-11-27 1983-03-31 Lilly Co Eli Improvements in the synthesis of dioxane analgesics
US4613610A (en) * 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
ATE62906T1 (de) * 1984-06-22 1991-05-15 Sandoz Ag Pyrazolanaloge von mevalonolakton und abkoemmlinge davon, verfahren zu deren herstellung und deren verwendung.
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US4735958A (en) * 1986-12-22 1988-04-05 Warner-Lambert Company Trans-6-[2-[2-(substituted-phenyl)-3- (or 4-) heteroaryl-5-substituted-1H-pyrrol-1-yl]-ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one inhibitors of cholesterol biosynthesis
DE3854854D1 (de) * 1987-07-10 1996-02-15 Hoechst Ag 3-Desmethyl-mevalonsäurederivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate auf Basis dieser Verbindungen, ihre Verwendung sowie Zwischenprodukte
DE3741509A1 (de) * 1987-12-08 1989-06-22 Hoechst Ag Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte

Also Published As

Publication number Publication date
KR890005089A (ko) 1989-05-11
DK497488A (da) 1989-03-09
JPH01121266A (ja) 1989-05-12
PT88442B (pt) 1992-11-30
AU620559B2 (en) 1992-02-20
AU2141288A (en) 1989-03-09
EP0306929A3 (en) 1990-02-07
PT88442A (pt) 1989-07-31
FI884080A7 (fi) 1989-03-09
NO883974D0 (no) 1988-09-07
US4906624A (en) 1990-03-06
FI884080A0 (fi) 1988-09-05
DK497488D0 (da) 1988-09-07
EP0306929A2 (en) 1989-03-15
NZ226063A (en) 1991-09-25

Similar Documents

Publication Publication Date Title
NO883974L (no) Fremgangsmaate for fremstilling av terapeutiske aktive tetrahydro-hydroksypyranon-derivater.
NO871266D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive kinazolin-derivater.
NO894630D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive kinuklidin-derivater.
NO904694L (no) Fremgangsmaate for fremstilling av terapeutisk aktive imidazolderivater.
NO901684D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 3-substituerte-2-oksindol-derivater.
NO870526D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive dikloranilin-derivater.
NO884231D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive imidazopyridin-derivater.
NO874032L (no) Fremgangsmaate for fremstilling av terapeutisk aktive catecholderivater.
NO883122D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive arylamid-derivater.
NO883485D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive piperidinyl-isokinolinforbindelser.
NO875488L (no) Fremgangsmaate for fremstilling av terapeutisk aktive alkansulfonanilid-derivater.
NO880667D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive arylpiperazinyl-alkylen-fenyl-heterocykliske forbindelser.
NO881762D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive benzazepinderivater.
NO891723L (no) Fremgangsmaate for fremstilling av terapeutisk aktive kinazolin-derivater.
NO884175D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske derivater.
NO167802C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzotiazepinderivater.
NO881884D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyrrolidin-derivater.
NO900972D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive naftalen-derivater.
NO871907D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive alkenamid-derivater.
NO882281D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyrazinamider.
NO900942D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive azacyklooktadien-derivater.
NO883959L (no) Fremgangsmaate for fremstilling av terapeutisk aktive fenolestere.
NO882282L (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyrazinamider.
NO890724L (no) Fremgangsmaate for fremstilling av terapeutisk aktive tetraazaacenaftylen-derivater.
NO890519D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive propanon-derivater.